Patents by Inventor Gregory LIZÉE

Gregory LIZÉE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T cell receptors with VGLL1 specificity and uses thereof
    Patent number: 12552851
    Abstract: Provided herein are tumor-antigen VGLL1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL1 are also provided.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: February 17, 2026
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Gregory Lizée, Cassian Yee
  • T CELL RECEPTORS FOR IMMUNOTHERAPY
    Publication number: 20250090560
    Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: December 5, 2024
    Publication date: March 20, 2025
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Gregory Lizée, Cassian YEE
  • T cell receptors for immunotherapy
    Patent number: 12178787
    Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 31, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gregory Lizée, Cassian Yee
  • T CELL RECEPTORS WITH VGLL1 SPECIFICITY AND USES THEREOF
    Publication number: 20230212256
    Abstract: Provided herein are tumor-antigen VGLL 1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL 1 are also provided.
    Type: Application
    Filed: May 21, 2021
    Publication date: July 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gregory LIZÉE, Cassian YEE
  • HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
    Patent number: 11684657
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 27, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gregory Lizée, Cassian Yee, Janos Roszik
  • SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
    Publication number: 20210170002
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 10, 2021
    Inventors: Gregory Lizée, Cassian Yee, Patrick Hwu, Janos Roszik
  • T CELL RECEPTORS FOR IMMUNOTHERAPY
    Publication number: 20200237820
    Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Inventors: Gregory Lizée, Cassian Yee
  • HLA-RESTRICTED VGLL1 PEPTIDES AND USE THEREOF
    Publication number: 20200040079
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 6, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gregory LIZÉE, Cassian YEE, Janos ROSZIK
  • SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
    Publication number: 20190169262
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 6, 2019
    Inventors: Gregory LIZÉE, Cassian YEE, Patrick HWU, Janos ROSZIK